Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Heal...
Product Name : Desvenlafaxine-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Intellipharmaceutics Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Zuranolone,Sertraline Hydrochloride,Escitalopram Oxalate,Citalopram,Duloxetine Hydrochloride,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2020
Lead Product(s) : Zuranolone,Sertraline Hydrochloride,Escitalopram Oxalate,Citalopram,Duloxetine Hydrochloride,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Desvenlafaxine in Treating Major Depressive Disorder.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Desvenlafaxine Succinate,Duloxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of MD-120 in Patients With Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LY03005,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2018
Lead Product(s) : LY03005,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LY03005,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2017
Lead Product(s) : LY03005,Desvenlafaxine Succinate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2016
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Seoul National University Bundang Hospital | Korea Cancer Center Hospital | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2016
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Seoul National University Bundang Hospital | Korea Cancer Center Hospital | Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Desvenlafaxine in Opioid-Dependent Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2014
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 03, 2013
Lead Product(s) : Desvenlafaxine Succinate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable